{"nctId":"NCT01691430","briefTitle":"A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents","startDateStruct":{"date":"2012-08"},"conditions":["Bacteriuria"],"count":185,"armGroups":[{"label":"2 cranberry capsules","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: 2 cranberry capsules"]},{"label":"2 placebo capsules","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Placebo"]}],"interventions":[{"name":"2 cranberry capsules","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. female residents;\n2. long term residents\n3. English speaking; and\n4. age ≥ 65 years.\n\nExclusion Criteria:\n\n1. residents that are not expected to be in the nursing home for at least one month (i.e., short term rehabilitation, pending discharge, terminal \\[life expectancy \\< 1 month\\]);\n2. residents who are on chronic suppressive antibiotic or anti-infective (i.e., mandelamine) therapy for recurrent UTI;\n3. residents with end stage renal disease on dialysis (they do not regularly produce urine);\n4. residents unable to produce a baseline clean catch urine specimen for collection;\n5. residents on warfarin therapy because of a potential interaction of warfarin and cranberry juice;\n6. residents with a history of nephrolithiasis because cranberry may increase the risk of nephrolithiasis;\n7. have an indwelling bladder catheter in place;\n8. have an allergy to cranberry products;\n9. are being treated with cranberry products;\n10. residence \\<4 weeks.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Urine Cultures With Bacteriuria (>100,000 Cfu/ml or >=100,000 Cfu/ml) Plus Pyuria (Any WBC)","description":"Clean catch urine cultures and urinalyses will be obtained every two months for each participant for study purposes.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Episodes of Symptomatic UTI","description":"Suspected UTI episodes that are recorded in the medical record by the primary provider will be reviewed by chart review, symptoms will be recorded, and two adjudicators will determine if the definition of symptomatic UTI is met.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Hospitalizations","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Deaths","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Antibiotic Prescriptions","description":"Chart review will be performed to determine the names and duration of antibiotic prescriptions prescribed by the primary provider on each participant.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1415","spread":null},{"groupId":"OG001","value":"1883","spread":null}]}]}]},{"type":"SECONDARY","title":"Bacteriuria With Multidrug-resistant Gram-negative Bacilli","description":"All urine culture data will be reviewed to determine presence of multidrug-resistant gram-negative bacilli (resistance to ≥3 of the following antibiotics: ampicillinsulbactam,cefazolin, ceftriaxone, ceftazidime, fluoroquinolones, piperacillin-tazobactam, meropenem, imipenem, and trimethoprim-sulfamethoxazole).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Antibiotic Prescriptions for Suspected UTI","description":"Chart review will be performed to determine the names and duration of antibiotic prescriptions prescribed by the primary provider on each participant's suspected UTI.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"692","spread":null},{"groupId":"OG001","value":"909","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Adverse Events in Participants","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1731","spread":null},{"groupId":"OG001","value":"1966","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adherence to Capsule Intake by All Participants","description":"measured by capsules removed from blister packs","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"82.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects With 1, 2, or 3 Episodes of UTIs","description":"Suspected UTI episodes that are recorded in the medical record by the primary provider will be reviewed by chart review, symptoms will be recorded, and two adjudicators will determine if the definition of symptomatic UTI is met.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":50,"n":92},"commonTop":["skin/soft tissue event","weight loss","Altered mental status","respiratory difficulty","GI disturbance"]}}}